AetoSense develops advanced air quality monitoring systems that enhance indoor air quality and optimise energy consumption by detecting ultrafine particles.

On a mission to revolutionise control strategies around air quality, AetoSense’s ultrafine particle monitoring solutions focus on the critical impact of airborne particles.

Led by a founding team of particle detection experts, AetoSense has developed proprietary optical detection and flow conditioning technology, which enables market-leading sensors’ sensitivity at a competitive cost.

AetoSense technology is offered to air handling systems retailers to provide healthier and more efficient working environments, with four ongoing pilot projects. These sensors will be fundamental for building management under the 2027 regulation on air quality monitoring in the EU and UK, opening up a $25bn market opportunity.

By inhibiting biofilms, BioTryp’s technology has the potential to revolutionise how we treat infection, providing a needed alternative to traditional antibiotic treatment.

Bacteria form biofilms as a protective shield against the immune system and antibiotics. Within biofilms, bacteria thrive, meaning that infections worsen, and treatments fail. With an initial focus on addressing the widespread issue of urinary tract infections (UTIs), BioTryp are developing novel small-molecule antibiofilms for bacterial infections. UTIs affect 400 million people annually, and biofilms in UTIs contribute to treatment failure and severe complications, making this a crucial challenge to solve.

BioTryp has already gained traction with multiple awards, grants and investment.

BravelyCultured is developing sustainable, skin-friendly biodegradable chemicals, with an initial focus on biosurfactants for personal and home care products.

Using proprietary marine microbes, BravelyCultured is replacing animal, tropical oil, and petroleum-based products, starting with eco-friendly biosurfactants to replace their petroleum-derived counterparts.

James Dunce and his team are on a journey to disrupt the surfactant market sustainably. Their technology reduces environmental pollution, avoids reliance on fossil fuels, minimises deforestation and significantly lowers CO2 emissions.

Cambridge Vision Technology has developed a groundbreaking, non-invasive approach to Alzheimer’s disease risk screening using just a simple eye exam.

Early detection of Alzheimer’s Disease is crucial for timely intervention and to slow the progression of the disease, but diagnosis is often lengthy and invasive.

This innovative technology analyses images of the retina, the back of the eye, which is an extension of the central nervous system. Subtle biomarkers in the retina can be detected with standard eye examination techniques. CVT uses AI to analyse these retinal images, identifying signs of Alzheimer’s at its earliest stages, even before symptoms appear.

The team secured a contract with the UK government to deliver their novel solution, following successful trials with academic partners.

Molyon is producing the next-gen energy storage, lithium-sulfur batteries, offering long-life batteries with twice the energy density of current lithium-ion batteries.

Next-generation batteries, which are lighter and smaller, are needed to support the net-zero transition. A commercial lithium-sulfur battery based on Molyon’s innovation provides superior performance at a lower cost, boosting the performance of weight-critical applications and enabling new modes of transport like electric aviation.

Molyon’s Li-S batteries, with superior chemistry, deliver twice the energy density of current lithium-ion batteries on the market at a fraction of the price due to more abundant materials.This breakthrough could double the range for transportation applications, tapping into an $85 billion global market.

Nanomation provides computer-vision software to the semiconductor industry, enabling clients to manufacture with advanced nanomaterials that are otherwise not usable within industry settings.

Using semiconducting nanomaterials makes electronics faster, more powerful and more efficient. They can add sensing, quantum and photonic functionalities to chips, which are not possible using traditional silicon alone. However, manufacturing with nanomaterials is currently impossible at a commercial scale, as they require manual integration that is too costly for industry.

Nanomation’s fully automated software solution means there is no need for manual integration. It provides highly accurate feature identification at the nanoscale, material characterisation and automated circuit layout design, enabling commercial development of advanced electronics applications.

Orbit is revolutionising mental health by making it as clear and actionable as physical health, using groundbreaking non-invasive neurotechnology.

Despite continuous and rapid technological advancements, mental health and wellbeing has been left behind and is still not well understood. By collecting unprecedented amounts of functional brain data, Orbit aims to illuminate (literally) how our brain works.

With a powerhouse team skilled in software, consumer hardware and neuroscience, Orbit is crafting a state-of-the-art wearable. Its mission is to decode and enhance cognition by creating the first-ever foundational model of the brain in the real world, using advanced, non-invasive techniques.

Protonera specialises in converting waste plastics into green hydrogen, providing sustainable waste management solutions to reduce reliance on fossil fuels.

There are three major bottlenecks in the plastic recycling market: the inability to process low-grade waste feedstocks, high operational costs from sorting contaminated feedstocks and poor revenue from low-value products.

Protonera aims to realise the scalability of a novel plastic upcycling technology, transforming waste plastics into green hydrogen and other value-added commodities. The team is creating a solution that degrades low-grade waste plastics that are not currently recycled and realises high profitability from product revenue.

VOLTQUANT offers the world’s first search engine for grid connections, empowering developers to connect seamlessly using a machine-learning-enabled platform.

The company’s focus on the UK’s advanced smart energy grid aims to tackle challenges associated with the transition to net-zero energy infrastructure, particularly the instability of renewable sources.

By providing solutions for stakeholders and navigating the complexities of the UK’s smart grid, VOLTQUANT aims to contribute to global efforts in sustainable energy development and assist other countries facing similar challenges in achieving their net-zero goals.

William Oak Diagnostics is developing a digitally integrated, point-of-care test for micronutrient deficiencies and anaemia, designed for use in pharmacies and at home.

With over 70 years of medical device commercialisation expertise, the team’s innovation is improving healthcare access and enabling early intervention. By shifting deficiency screening from primary care to the community, the solution addresses widespread issues such as iron deficiency anaemia and other serious nutrient deficiencies, helping reduce the burden on GPs and the need for costly hospital-based diagnostics.

William Oak’s novel approach simplifies blood collection and delivers clear, quantifiable results through a user-friendly mobile app. The technology has the potential to personalise nutritional health monitoring, empowering individuals to take control of their wellbeing.

Xterna offers novel solutions for cell-type specific drug delivery, leveraging advanced biotechnology to improve therapeutic outcomes.

Xterna’s technology identifies different cell types in the human body through engineered cell-specific binders. These binders could be used for diagnostics or coupled with therapeutics to aid drug delivery to specific cells.

Drugs widely diffuse in the body, resulting in ineffective doses at diseased organs and toxic accumulation in non-target tissues. For successful targeting, drugs must be combined with modalities that home them to specific cells. While the crowd focuses on classical surface proteins, Xterna focuses on nature’s newly identified surface barcode.

Cambridge Adaptive Testing delivers rapid, precise mental health assessments in under 60 seconds, utilising innovative technologies to identify individuals in need of support.

Its Class LA medical device platform uses adaptive testing to personalise measurement, making it efficient, engaging and ideal for repeated use. Built for organisations, it identifies who needs support and instantly connects them to resources, tracking change over time to evaluate the impact of interventions. With seamless delivery at scale, the powerful analytics dashboard provides real-time insights. An organisational heatmap enables leaders to tailor approaches to employee wellbeing and measure ROI.

Scalable, evidence-based and designed for today’s organisations, the team is redefining how mental health is measured and managed.

Complex, three-dimensional tissue cultures have been identified as a solution to the inefficiency crisis at the heart of drug discovery, with organ-on-chip models shown to be capable of screening out ineffective drug assets before they incur significant costs. However, extracting the data needed to realise this potential has proven intractable. Until Electra Bio solved it.

The team has built a system which blends biology and embedded sensors to create living electronics, accelerating the journey from concept to cure, opening the way for data rich experimentation and the data-driven future of drug discovery.

Gastrobody Therapeutics is developing ultra-stable antibody mimetics capable of withstanding the harsh acidic and protease-rich conditions of the GI tract.

The team aims to utilise its patented Gastrobody platform to develop orally administered biologics, transforming the way we treat gastrointestinal tract diseases such as Crohn’s disease and Ulcerative Colitis.

The Gastrobody platform combines the exquisite specificity of antibodies with the stability of certain soybean proteins to generate a novel class of biologics which can be delivered directly to the GI tract rather than systemic administration by injection, used in existing antibody-based therapies.

Pinepeak develops physics-driven technology to predict wildfire risk and behaviour across any terrain, anywhere in the world.

Born out of jet engine research at the University of Cambridge and built by a world-class team in combustion science, AI and geospatial intelligence, Pinepeak delivers ultra-granular, physics-driven wildfire forecasts at the asset level – empowering re/insurers to price risk more accurately, emergency responders to act faster and communities to better protect lives and the environment.

Using AI to forecast brain disease progression, Prodromic is accelerating the search of new treatments to enable earlier diagnosis, smarter clinical trials and more personalised treatment.

Its SaaS solutions accurately predict brain disease trajectories, starting with a validated use case in dementia. Prodromics’ products de-risk the development of diagnostic biomarkers, make clinical trials of new therapeutics more efficient and effective and improve treatment decision-making for patients and health systems.

Validated on 20,000+ patients from around the world, the team’s multimodal AI engines separate “clinically indistinguishable” individuals to predict disease trajectories over 5 years.

Sqwish is the smart performance layer sitting between AI apps and model providers – dynamically optimising speed, performance, cost and reliability at scale.

Founded by Dr Ushnish Sengupta and Federica Freddi, Sqwish acts as the “autopilot” for AI engineering. Its adaptive performance platform for generative AI apps and agents uses real-time reinforcement learning to optimise prompts, models and context.

Built for teams deploying AI in production, it goes beyond technical metrics – cutting costs, boosting speed and improving accuracy to deliver AI that learns from every interaction and drives measurable outcomes.

Trismik is dedicated to revolutionising the field of Large Language Model (LLM) testing, providing an adversarial platform that enhances model accuracy, safety and alignment with societal values.

As AI becomes embedded in everyday tools, the need to test large language models for safety, reliability and bias continues to grow – and so do the challenges.

Trismik’s adaptive platform gives AI teams a faster, smarter way to evaluate generative models, rigorously checking for real-world risks like hallucinations and factual errors without compromising on performance or values. By making trustworthy AI possible at scale, Trismik is helping organisations build technology people can rely on.

AdcoTx is developing a novel therapeutic to improve first‑line treatment options for colorectal cancer patients worldwide.

AdcoTx is a single‑asset biotech startup translating University of Cambridge oncology research into a novel therapeutic for colorectal cancer (CRC).

The virtual company’s lead asset is an antibody–drug conjugate (ADC) targeting LGR5, a well‑validated marker associated with tumour growth. Currently in late‑stage pre‑clinical development, the asset has demonstrated in vivo proof of principle, with activity against tumour cells.

With CRC set to become a $50 billion opportunity by 2032, AdcoTx is focusing on achieving a Phase I exit milestone with pharma.

AILA Biotech is developing a CNS-targeted gene delivery platform that enables ultra-low-dose viral therapies for chronic neuroinflammatory diseases.

AILA Biotech’s next‑generation Adeno-associated virus (AAV) gene delivery platform is designed specifically for diseases of the central nervous system (CNS).

Current AAV approaches often require very high doses, cause liver toxicity and are too expensive to scale. AILA’s platform enables precise, CNS‑targeted delivery of neurotherapeutics at ultra‑low doses, 5,000–10,000x lower AAV doses than traditional gene therapy, reducing systemic exposure and manufacturing costs.

Emerging from immunology and gene therapy research at the University of Cambridge, the technology is being developed to support disease‑modifying treatments for chronic neuroinflammation, with primary progressive multiple sclerosis (PPMS) as the first indication.

Auralytica creates holographic hydrogel sensors that provide real‑time, low‑cost molecular data with a first market to improve food quality, safety and monitoring.

Auralytica is a deep‑tech company developing holographic hydrogel sensors for real‑time molecular sensing. The technology offers a low‑cost, dye‑free and electronics‑free approach to monitoring quality and safety across food and beverage supply chains.

Auralytica’s first applications focus on in‑package monitoring, providing continuous insight into freshness and spoilage to reduce waste and improve safety.

Emerging from materials and chemistry research, the company is working towards a new generation of intelligent indicators that could redefine how quality information is communicated, including the future of use‑by dates.

Cambridge Cryogenics designs and manufactures solid‑state milliKelvin refrigeration platforms for quantum computing, sensing and advanced materials research.

Cambridge Cryogenics designs and manufactures ultra‑low‑temperature solid‑state refrigeration systems for quantum science and technology.

Its compact milliKelvin platforms support quantum computers, sensors, communication devices and advanced materials research, with deployments across research and industrial settings worldwide. Built on patented core technology, the systems offer reliability, scalability and integration with emerging quantum hardware.

Alongside its established research markets, the company is exploring hardware development for applications across adjacent sectors to diversify into emerging cryogenic markets, including medical, space and energy.

Cosysense uses AI agents and digital twins to optimise HVAC systems in commercial buildings, reducing energy costs, emissions and operational inefficiencies.

Cosysense delivers AI‑native control systems for heating, ventilation and air conditioning in commercial buildings. By combining real‑time sensor data, building management systems and digital twins, the platform enables continuous, automated optimisation of building performance.

AI agents automate systems every 15 minutes, balancing energy use, comfort and operational stability. Cosysense’s approach reduces electricity costs and carbon emissions while preventing performance drift common in legacy HVAC systems, improving overall energy efficiency. The proprietary technology is designed to integrate with existing infrastructure, making advanced building intelligence accessible without complex retrofitting.

Neela Biotech produces carbon‑negative aviation fuel by combining synthetic biology, AI and existing biogas infrastructure at competitive cost.

Neela Biotech is building a scalable pathway to carbon‑negative fuels using controlled microbial upcycling. By leveraging existing biogas infrastructure, its proprietary Controlled Microbial Upcycling (CMU) platform converts waste streams into renewable platform chemicals that can be used as drop‑in feedstocks for aviation fuel and other industries.

Advances in AI-driven synthetic biology are used to optimise bioprocess performance and scale. Neela’s approach avoids competition with food, land or water resources and is designed for rapid deployment, offering a practical route to decarbonising aviation while working within established industrial systems.

NeuroFold develops minimally invasive spinal implants that can be delivered through a needle to provide accessible neuromodulation for chronic pain.

NeuroFold’s patented next‑generation spinal cord stimulation technology is designed to be less invasive and more accessible to patients with chronic pain. The company’s implantable devices are engineered to be delivered through a needle, avoiding major surgery while enabling precise neuromodulation.

Emerging from bioelectronics research at the University of Cambridge, the technology extends seamlessly across both spinal and brain–computer interface applications. By reducing procedural complexity and broadening access, NeuroFold aims to set a new standard for scalable, clinically adoptable neuromodulation therapies worldwide.

Satorus Group builds AI agents that automate data collection, analysis and reporting workflows for intelligence and investigation teams.

Satorus Group develops AI agents designed to support intelligence investigations by automating complex information workflows. Its platform ‘Sidney’ scans across open, deep and alternative data sources to identify digital footprints, extract relevant information and structure analysis through natural‑language queries.

By reducing manual research and report preparation, Satorus enables investigators to focus on judgment and decision‑making rather than data handling. The system is designed to integrate into existing intelligence processes, producing outputs that can be repeatedly queried before being formulated into an intelligence report in a format tailored to organisational requirements.

Senesys.Bio is developing nanomedicine platforms to selectively deliver senolytic therapies for age‑related disease.

Senesys.Bio is a University of Cambridge spinout developing a novel nanomedicine platform designed to selectively target and eliminate senescent cells, which drive chronic inflammation, fibrosis and tissue degeneration.

Its proprietary NanoJAGGS™ technology enables targeted delivery of senolytic drugs to diseased cells, addressing safety and selectivity issues that have limited earlier approaches.

The company’s initial focus is on idiopathic pulmonary fibrosis, with broader potential across ageing‑related conditions. By solving the delivery challenge, Senesys.Bio aims to unlock a new class of disease‑modifying therapies.

Latom is building an agentic AI platform for interactive visual learning design.

Combining the team’s expertise in education and technology, their AI-powered tool streamlines the creation of accurate, accessible 2D and 3D visuals – helping educators produce engaging content faster, with seamless integration into existing learning platforms.

siliXon blends AI and electronic engineering to help people intuitively design circuits using natural language.

Built to work alongside engineers, the team’s software automates Printed Circuit Boards (PCBs) using natural language. For a component that underpins modern electronics, siliXon’s breakthrough turns written input into functional electronic designs in minutes, accelerating the hardware design process without replacing it.

Verascient provides hallucination detection and correction for AI in regulated and accuracy-critical environments.

The team’s mission is to protect the integrity of information in the age of AI by building the trust layer that makes safe, reliable AI possible across every sector.

Aizen is a credit data startup driving financial inclusion with AI-powered financial passports that enable fairer credit decisions using real-time income, rent and spending data.

AshGold Africa reduces education inequality by expanding energy access. In Kenya, it deploys solar projects and digital tools to schools, creating green jobs and climate-resilient learning environments.

Atera Analytics integrates AI, energy and network planning to optimise EV energy infrastructure and logistics for smarter, scalable deployment across the UK, Europe and USA.

Borderline is creating the data backbone for emerging market investment opportunities – converting fragmented project pipelines into structured, diligence-ready opportunities for capital allocators.

Cambridge Mobilytics turns EV charging data into actionable intelligence, building predictive AI models and real-time analytics to support smarter decisions across the e-mobility sector.

Dielectrix develops advanced materials for next-gen semiconductors, enabling energy-efficient, scalable devices and supporting architectures like CFET to meet growing demand for AI and deep learning.

Egg Advisor is a digital platform guiding women through the egg freezing journey with evidence-based insights, personalised tools and one-to-one support for informed fertility choices.

Greenharvest is tackling the food sustainability crisis by using climate modelling, soil analysis and satellite data to predict crop potential and guide resilient agricultural planning.

Heartly helps individuals prevent cardiovascular disease through personalised education, data-driven insights and coaching – bridging the gap between public resources and private care with accessible, expert-led support.

HED is redefining how patient experience is measured in personalised health tech. Temporal Experience Tracing™ captures real-time changes in how patients feel, offering insights into treatment impact and enabling responsive, human-centred care.

iFlame accelerates product innovation with a multi-agent AI system that combines automated collaboration and human input to deliver data-driven, scalable and creative product strategies.

Healthtech startup IntolerSense uses AI-enhanced food logging and symptom tracking to uncover hidden intolerances, giving users and clinicians faster, more accurate insights into dietary triggers.

Med Arcade simplifies clinical data with a user-first agentic AI platform that streamlines patient records, reduces cognitive load and frees up time for better care.

MENRVA is an AI SaaS platform streamlining art discovery for businesses, matching them with the exact artists and artworks through personalised recommendations and direct connection tools.

Myta Bio creates biomimetic industrial chemicals from natural ingredients, starting with Myty™ – a mussel-inspired adhesive offering a safer, sustainable alternative to petrochemical-based glues.

Polytecks is developing a novel method for measuring body surface potentials using wearable e-textiles to improve heart disease detection – starting with early screening for valvular disease in dogs.

PsyPress (formerly Dulce Cerebrum) is pioneering glycosylation analysis – cracking the “sugar code” – to detect early psychosis through powerful AI models and everyday speech for personalised mental health diagnostics.

RetroAnalytica uses AI and climate modelling to predict heat loss, assess retrofit potential and optimise energy efficiency across buildings and property portfolios for decarbonisation.

SafeTide is developing low-cost stabilisation technology that keeps delicate medicines like insulin stable at room temperature, reducing waste and improving access to life-saving treatments.

The Surpluss is a B Corp climate tech platform helping businesses trade excess resources, reducing waste and unlocking circular value across global supply chains.

Yacson QuantumBio analyses plant-based therapeutics to personalise IBD care, using organoid models and epigenetic biomarkers to guide treatment selection and reduce reliance on animal testing in drug discovery.

Zenithon AI accelerates fusion research with machine learning tools that reduce plasma simulation times from months to seconds – enabling faster, smarter design across energy and engineering sectors.